Health Care/Hospital
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
NANJING, China, Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement with Roche for the development and commercialization of SIM0660, a tri-specific antibody targeting...
2026-09-01 20:28
3289
Time is Running Out to Submit a Claim in the Asbestos Corporation Limited insolvency proceedings
The deadline is September 10, 2026. NEW YORK, Sept. 1, 2026 /PRNewswire/ -- The following statement is being issued by Kroll Restructuring Administration and Raymond Chabot Inc. regarding the Asbestos Corporation Limited insolvency proceedings. With less than one month remaining before the Septe...
2026-09-01 20:13
2691
QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery
Joint test on IonQ Forte hardware lands within 4% of benchmark, clearing the chemical-accuracy bar for enzyme active-site modeling via Amazon Braket PALO ALTO, Calif., Sept. 1, 2026 /PRNewswire/ -- QC Ware today announced a technology demonstration of a hybrid quantum-classical chemistry workflow...
2026-09-01 20:00
2388
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Pa...
2026-09-01 19:30
2216
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expec...
2026-09-01 19:15
2470
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of lega...
2026-09-01 19:00
2554
JIANGXI BIO Announced 2026 Interim Results
Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody Interim Results Highlights Key Financial Indicators * Revenue amounted to RMB83.3 mn; gross profit amounted to RMB60.3 mn, ...
2026-09-01 14:44
6392
Siemens Healthineers showcases its AI-powered technological innovations to redefine healthcare delivery in Southeast Asia
* Spotlights how scaling AI and big data can make clinical pathways more efficient * Hosts its second ASEAN CEO Summit to drive collaboration amongst healthcare leaders to redefine care delivery in Southeast Asia * Unveils new regional report "Strengthening Stroke System Readiness Across AS...
2026-09-01 11:00
4161
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Company to host a corporate update call Tuesday, September 1st at 8:00am ET
SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited
2026-09-01 07:23
5247
Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
The next generation in skin resurfacing technology is available to Australian health care practitioners beginning 1 September 2026 LAVAL, QC, Sept. 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics busines...
2026-09-01 06:00
2681
Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases
SUZHOU, China, Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $15 million Seed+ financing round. This round was led by MPCi, with part...
2026-08-31 21:00
2799
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...
2026-08-31 20:38
4943
T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma BEIJING, Aug. 31, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") today announced that its investigational allogeneic CAR-T cell therapy MT027 ha...
2026-08-31 20:00
1325
Fosun International Holds 2026 Interim Results Presentation: Unlocking Core Pathways, Accelerating Growth in Industries where we Excel
HONG KONG, Aug. 31, 2026 /PRNewswire/ -- On the morning of 28 August, Fosun International held its 2026 interim results presentation in Hong Kong. This marks Fosun's return to Hong Kong to hold a results presentation for the first time in six years. The results presentation was attended by Guo Gu...
2026-08-31 17:43
4150
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
* Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer * Publication of offer prospectus follows pre-announcement on July 20, 2026 * Largest individual shareholder committed to tender all of its PolyPeptide shares into offer * Main offer period expected ...
2026-08-31 13:00
1982
SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring
MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with...
2026-08-31 12:17
1499
HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026: A New Era in Wrist-Based Blood Pressure Management
MUNICH, Aug. 31, 2026 /PRNewswire/ -- The European Society of Cardiology Congress (ESC Congress 2026), one of the world's most influential academic gatherings in cardiovascular medicine, officially kicked off today in Munich, Germany. Huawei showcased its latest innovations in health and fitness,...
2026-08-31 12:04
1797
Amai Proteins' sweelin® Approved for Sale in Israel, Opening the Market to a New Generation of Reduced-Sugar Food and Beverage Products
Third regulatory approval in less than six months enables food and beverage manufacturers to commercialize products sweetened with sweelin® in Israel. REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Amai Proteins announces that the Israeli Ministry of Health has officially approvedsweelin® as a no...
2026-08-31 09:00
2206
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
* Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant and have received at lea...
2026-08-31 09:00
2503
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion
SHANGHAI, Aug. 30, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend. Building on its inaugural interim d...
2026-08-31 08:00
2174
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23116
